Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 DiabetesRalph A. DeFronzo, Steven C. Griffen, David W. Boulton et al.|Diabetes Care|2013Cited by 289
Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjectsSreeneeranj Kasichayanula, David W. Boulton, Xuejun Liu et al.|Diabetes Obesity and Metabolism|2010Cited by 90
Steering Away from Current Amoxicillin Dose Reductions in Hospitalized Patients with Impaired Kidney Function to Avoid Subtherapeutic Drug ExposureCornelis Smit, Marc Pfister, Swapnoleena Sen et al.|Antibiotics|2022Cited by 4
of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 DiabetesRalph A. DeFronzo, Steven C. Griffen, Marcus Hompesch et al.|Unknown|2013Cited by 0